--- title: "Weekly Recap | Bristol Myers Squibb +2.9%, breast cancer Phase 3 cut risk by 59%" type: "News" locale: "en" url: "https://longbridge.com/en/news/302949568.md" description: "Bristol Myers Squibb (BMY) added 2.9% for the week, closing at $61.48 and outperforming the S&P 500 (down 0.47%) by roughly 3.37 percentage points. The week unfolded as a rally that gave back some ground: the stock opened lower on Monday, touched a weekly low of $58.435, then pushed steadily higher through Thursday to a weekly high of $63.59 before easing to $61.48 on Friday. Weekly amplitude came to about 8.68%, and average daily volume ran around 15." datetime: "2026-10-24T06:01:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302949568.md) - [en](https://longbridge.com/en/news/302949568.md) - [zh-HK](https://longbridge.com/zh-HK/news/302949568.md) generator: "portal-rs" --- # Weekly Recap | Bristol Myers Squibb +2.9%, breast cancer Phase 3 cut risk by 59% ## The Week Bristol Myers Squibb (BMY) added 2.9% for the week, closing at $61.48 and outperforming the S&P 500 (down 0.47%) by roughly 3.37 percentage points. The week unfolded as a rally that gave back some ground: the stock opened lower on Monday, touched a weekly low of $58.435, then pushed steadily higher through Thursday to a weekly high of $63.59 before easing to $61.48 on Friday. Weekly amplitude came to about 8.68%, and average daily volume ran around 15.85% above the median, reflecting continued active trading.\\n\\n## Key Events This week’s news centred on development-stage data. On Monday, the company said it would present Phase 2 data for Pumitamig in lung cancer at ESMO 2026. Tuesday brought a sharp intraday move and a 3.39% single-day gain. On Thursday, reports pointed to major consumer releases supporting second-half performance and a projected record full-year profit. Friday was the busiest day: Bristol Myers announced that Izalontamab Brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in advanced HR+/HER2- breast cancer in the Phase 3 PANKU-Breast01 study; presented Phase 1 results for Zolacabtagene Autoleucel in highly active relapsing and progressive multiple sclerosis at MSToronto 2026; and expanded its oncology data partnership with Tempus AI through 2031, alongside a collaboration with Pathos AI on drug development. Late Friday, the company disclosed a patient death in an early-stage autoimmune disease trial, and shares fell; a spokesperson later said the fatal event occurred after the trial pause.\\n\\n## Analyst Ratings Among institutions covering Bristol Myers Squibb, 6 rate it buy, 4 overweight, 17 hold, 1 sell, and 1 no opinion, for a total of 29. The consensus rating is hold, with a consensus target of $65.41667, implying about 6.40% upside from the current price. The target range is wide, from $41.00 to $82.00, pointing to meaningful divergence across analysts. Within the pharmaceutical industry, the company ranks 2nd among 203 peers in rating terms.\\n\\n## The Week Ahead The market turns to Bristol Myers Squibb’s fiscal Q3 2026 results due before the open on 29 October, with consensus estimates of $0.9518 in EPS and $12.7 billion in revenue. Before that, 27 October brings US durable goods orders, FHFA house prices, S&P/Case-Shiller home price indices, new home sales, and consumer confidence. The follow-through on the multiple sclerosis trial death disclosed Friday, along with further interpretation of the breast cancer Phase 3 data, will also be watched.\\n\\n## In Short This week Bristol Myers Squibb saw divergent research signals: breast cancer Phase 3 data landed positively, while the autoimmune disease trial death created downward pressure. The analyst picture is similarly mixed—consensus sits at hold, buy and overweight together account for 10 of 29 ratings, and the consensus target of $65.42 stands about 6.40% above spot, with a wide target range. On valuation, the stock trades around 13.53x P/E, 5.63x P/B, and a 4.10% dividend yield. The next question is whether next week’s earnings can underpin the research headlines, and how far the safety event weighs on the relevant pipeline.\\n\\n*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*\\n ### Related Stocks - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) ## Related News & Research - [Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause](https://longbridge.com/en/news/302909326.md) - [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md) - [Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial](https://longbridge.com/en/news/301263394.md) - [Amazon.com, Inc. $AMZN Stock Sold by Cohen Klingenstein LLC](https://longbridge.com/en/news/302980467.md) - [Google's privacy policy lets connected Gmail and Photos data personalize ads](https://longbridge.com/en/news/302987424.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**